Japanese AIDS Vaccine Enters Clinical Trial
5 Point Safety Belt,Safety Harness Belt,Three Point Safety Belt,Full Body Harness Safety Belt Shandong Binzhou Yong'an Labor Protection Factory , https://www.zhuqiangsafetybelt.com
Recently, the International AIDS Vaccine Initiative (IAVI) and Japan's DNAVEC Co., Ltd. jointly announced that Japan's domestic AIDS vaccine has entered clinical trials in the United Kingdom and Rwanda. Clinical trials last about one and a half years. After the safety is confirmed, the vaccine may become the first AIDS vaccine put into practical use in the world.
The vaccine uses the "Sendai Parainfluenza virus" that does not cause human diseases. The virus is implanted with a gene that transcribes the proteins held by the virus and is then injected into the nasal cavity of the uninfected person. The Sendai parainfluenza virus will disappear after 1 to 2 weeks, but the protein that is transcribed from the implanted gene will promote the body's immune system to produce HIV-resistant substances.
It is reported that DNAVEC Co., Ltd. is a biotechnology company and is based on the National DNAVEC Research Institute for Gene Therapy Technology Development. It is headquartered in Tsukuba City, Ibaraki Prefecture, Japan.